Last reviewed · How we verify
NCT04769479
A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
Phase 1 trial testing acoramidis in Amyloidosis in 14 participants. Completed in 3 September 2021.
4 August 2021
Quick facts
| Lead sponsor | Eidos Therapeutics, a BridgeBio company |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 28 March 2021 |
| Primary completion | 4 August 2021 |
| Estimated completion | 3 September 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- acoramidis (ACORAMIDIS) — full drug profile →
Conditions studied
- Amyloidosis — all drugs for Amyloidosis →
Sponsor
Eidos Therapeutics, a BridgeBio company — full company profile →
Who can join
Adults 18 to 65, any sex, with Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04769479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of acoramidis
Trials testing the same drug.
- NCT03860935 — Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy · Phase 3 · completed
Other recruiting trials for Amyloidosis
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
Other Eidos Therapeutics, a BridgeBio company trials
Trials by the same sponsor.
- NCT04988386 — Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants · Phase 3 · active not recruiting
- NCT04418024 — Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy · Phase 3 · withdrawn
- NCT03860935 — Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy · Phase 3 · completed
- NCT03458130 — Study of AG10 in Amyloid Cardiomyopathy · Phase 2 · completed
- NCT03294707 — Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04769479 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eidos Therapeutics, a BridgeBio company
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04769479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing